Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea
Avance Clinical CEO, Yvonne Lungershausen said the decision to open clinical operations in Seoul followed increasing demand from later phase US biotechs, as well as CRO partners for access to the region's scientific excellence and patient populations.
- Avance Clinical CEO, Yvonne Lungershausen said the decision to open clinical operations in Seoul followed increasing demand from later phase US biotechs, as well as CRO partners for access to the region's scientific excellence and patient populations.
- "The new South Korean operations also offer a strategic presence for Avance Clinical's CRO partners conducting multi-regional or global trials.
- Avance Clinical is focussed on accelerating drug development for its biotech clients, from preclinical stages through to Phase III.
- Book a meeting with the team at the Australian Pavilion at BIO Korea to meet with our team of clinical trial experts.